5nance5nance
5nance5nance
HomeScreens
LOGINGET FREE ACCOUNT

Neuland Laboratories Ltd.

•
neulandlabs.comBSE: 524558NSE: NEULANDLAB
Market Cap₹ 30,197 Cr.
Current Price
High / Low₹ 24,225 / 11,500
Stock P/E60.8
Book Value₹ 1,568
Price to Book8.26
Dividend Yield0.14 %
ROCE27.5 %
ROE21.5 %
Face Value₹ 10

Add ratio to table

ABOUT

AI Sector View

AI GENERATED

Healthcare

Buy

This stance relies on proxies and positioning because no direct pharma-export or healthcare operating series exists in the dataset. The depreciated currency at 95.23 (Sep/26) can support export earnings, inflation at 4.45% (Jul/26) is manageable for a defensive sector, and consumer spending remains large at INR 44743 billion (Jun/26). Strong FPI inflow of INR 10620 crore over 3 months to 2026-08-31 from INR -11381 crore in the prior 3 months adds a real sector-specific tailwind, but confidence stays capped because the fundamental drivers are indirect proxies.

Confidence
50%
View full sector analysis →

PROS

  • Company has delivered good profit growth of 35.2% CAGR over last 5 years
  • Company has a healthy return on capital (ROCE) of 28.2%
  • Company has a good return on equity (ROE) track record: 3 Years ROE 22.2%
  • Latest quarter profit grew 974.9% YoY, showing strong momentum
  • Operating margins have improved to 28.3% from 23.6%
  • Company has delivered good sales growth of 16.6% CAGR over last 5 years

CONS

  • Receivables are growing faster than sales - a possible quality concern
  • Total debt has risen sharply - up 44.6% year on year
  • Stock is trading at 8.3x its book value
  • Though reporting repeated profits, the company pays out little dividend (12.0%)
  • Rich enterprise valuation - EV/EBITDA of 25.3x

* The pros and cons are machine generated based on quantitative rules.

Peer comparison

HealthcareHealthcarePharmaceuticals & Drugs
Part ofNIFTY TOTAL MKTNIFTY SMLCAP 50NIFTY 500NIFTY SMLCAP 250
S.No.Name
1.SUNPHARMA1842.0036.54441957.500.872901.2326.5315299.8810.9819.1128.81
2.DIVISLAB9326.0084.64247576.000.32902.0065.503080.0027.8021.5140.75
3.TORNTPHARM4975.0086.76189233.010.76566.003.284921.0057.3219.2733.81
4.ZYDUSLIFE1119.5024.74111670.550.09990.20-34.908017.0023.9721.3924.54
5.CIPLA1365.0032.72110272.680.95785.55-39.187119.284.1316.0016.73
6.LAURUSLABS1970.3597.37106460.420.10362.07123.942026.3129.1018.2031.50
7.DRREDDY1161.0030.0796906.380.69435.60-69.108099.80-5.2113.7510.63
8.AUROPHARMA1675.4525.9796401.690.241032.0325.229150.3517.4412.7620.54
9.LUPIN2096.0017.3495842.920.861416.9816.018276.8934.2828.8629.59
10.MANKIND2277.0046.0494050.370.04574.0929.124030.5912.8913.2426.30
11.GLENMARK2416.9037.9468210.880.10482.83927.884018.4831.3520.3520.03
12.NEULANDLAB23536.2060.6630196.680.14147.67962.40641.58119.1627.5034.74
Detailed Comparison with:

Quarterly Results

Standalone Figures in Rs. Crores / View Consolidated

Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
363418393385440311398328293514440776642
266280272278316250312278258359363469453
Operating Profit971371211071246186513415577307189
OPM %26.79%32.87%30.69%27.74%28.17%19.73%21.70%15.46%11.71%30.16%17.50%39.54%29.47%
2325254607828128
Interest2444312255777
Depreciation14151516161616172023242527
Profit before Tax841211049213049128391712954287198
Tax %25.49%26.64%22.24%26.57%24.53%34.16%20.50%28.86%21.12%25.25%25.54%25.96%25.40%
Net Profit62898168983210128149640213147
48.5069.4262.9052.7076.6524.9179.0321.6210.6875.1831.50165.65114.86

Profit & Loss

Standalone Figures in Rs. Crores / View Consolidated

Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
5795276677639379511,1911,5591,4772,0232,372
4734776096617908099201,0971,1551,4501,644
Operating Profit1065058101146142271462322573728
OPM %18.26%9.49%8.68%13.30%15.63%14.95%22.78%29.64%21.82%28.34%30.69%
15341621013973031
Interest211916221813131482426
Depreciation1922263140495360669298
Profit before Tax6714205210582215401345488668
Tax %30.30%12.79%18.61%69.75%23.50%22.27%24.21%25.24%24.89%25.55%25.62%
Net Profit461216168064163300259363497
EPS41.5810.5912.8312.3862.5849.52127.14233.51202.20283.01—
Dividend Payout %0.00%0.00%9.54%16.16%7.99%10.10%7.87%6.00%5.93%12.01%—

COMPOUNDED SALES GROWTH

10 Years:
15%
5 Years:
17%
3 Years:
19%

COMPOUNDED PROFIT GROWTH

10 Years:
30%
5 Years:
35%
3 Years:
31%

STOCK PRICE CAGR

10 Years:
37%
5 Years:
68%
3 Years:
88%
1 Year:
51%

RETURN ON EQUITY

10 Years:
14%
5 Years:
18%
3 Years:
22%
Last Year:
21%

Balance Sheet

Standalone Figures in Rs. Crores / View Consolidated

Corporate actions

2026

Jul 24

₹ 3.40

Rs.34.0000 per share(340%)Final Dividend

2025

Jul 18

₹ 1.20

Rs.12.0000 per share(120%)Final Dividend

2024

Jul 12

₹ 1.40

Rs.14.0000 per share(140%)Final Dividend

2023

Jul 11

₹ 1

Rs.10.0000 per share(100%)Final Dividend

2022

Jul 14

₹ 0.50

Rs.5.0000 per share(50%)Final Dividend

2021

Jun 29

₹ 0.30

Rs.3.0000 per share(30%)Final Dividend

2020

Nov 10

₹ 0.20

Interim Dividend

2020

Feb 18

₹ 0.20

Interim Dividend

2016

Aug 4

₹ 0.20

Rs.2.0000 per share(20%)Dividend

Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital991313131313131313
2232356836937698239751,2641,5051,853
19233925228518323812554109261
Trade Payables89129124120157123178199261279
37235959119202186288302290523
Total Liabilities8851,0711,1301,2301,3241,3821,5791,8312,1782,928
4364455126236977487388059551,177
Capital Work in Progress20126104241720414645209
888874111092
135175193220248265279350386510
0000000374316541
Cash & Bank12173746181959115257354
274300276310337326462140111135
Total Assets8851,0711,1301,2301,3241,3821,5791,8312,1782,928

Cash Flows

Standalone Figures in Rs. Crores / View Consolidated

Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
5515756119481282260318348
Cash from Investing-42-116-77-49-84-96-61-150-298-424
Cash from Financing-010512-5-11438-136-692521
-3042-93414144-55

Ratios

Standalone Figures in Rs. Crores / View Consolidated

Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026

Shareholding Pattern

Numbers in percentages

Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
32.7232.6432.6832.6832.6832.6432.6332.6332.62
25.7226.4623.8622.1221.6920.6020.9020.4621.08
6.396.389.0910.9711.5713.5514.7215.8416.52
0.400.400.400.400.400.400.000.000.00
34.7634.1133.9733.8433.6732.8131.7631.0729.79

Documents

Corporate disclosures, annual reports, credit ratings, and concall transcripts

2026-09-09
Analysts/Institutional Investor Meet/Con. Call Updates

2026-09-09 - Intimation about Schedule of Analyst / Institutional Investor Meeting on September 15, 2026 and September 17, 2026

2026-09-07
Updates

2026-09-07 - Neuland Laboratories Limited has informed the Exchange regarding 'Disclosure under Regulation 30 of SEBI Listing Regulations'.

2026-08-25
Credit Rating

2026-08-25 - Neuland Laboratories Limited has informed the Exchange about Credit Rating

2026-08-23
Copy of Newspaper Publication

2026-08-23 - Neuland Laboratories Limited has informed the Exchange about Copy of Newspaper Publication

2026-08-14
Updates

2026-08-14 - Neuland Laboratories Limited has informed the Exchange regarding 'Intimation Regarding Completion Of US FDA Inspection'.

2026-08-10
Analysts/Institutional Investor Meet/Con. Call Updates

2026-08-10 - Transcript of the Earnings Call conducted on August 5, 2026

2026-08-07
Analysts/Institutional Investor Meet/Con. Call Updates

2026-08-07 - Neuland Laboratories Limited has informed the Exchange about Schedule of meet

2026-08-06
Copy of Newspaper Publication

2026-08-06 - Neuland Laboratories Limited has informed the Exchange about Copy of Newspaper Publication

2026-08-05
Analysts/Institutional Investor Meet/Con. Call Updates

2026-08-05 - Audio Recording of the Earnings call conducted on August 5, 2026

News

Recent coverage and analyst commentary for NEULANDLAB

Loading news…

🤖

AI Stock Analyst

Neuland Laboratories Ltd.

🔒

Sign in to Chat with AI

Log in with your 5nance account to ask institutional questions about performance, financials, and outlook.

✨ Sign In to Chat

Free 5nance Account

5nance5nance

Stock analysis and screening tool

5nanceAI © 2020-2026

Made with ❤️ in India.

Data provided by Accord Fintech

Terms & Privacy.

Product

PremiumWhat's new?Learn

Team

About usSupport

Theme

5nance5nance

Product

PremiumWhat's new?Learn

Team

About usSupport

Theme

5nanceAI © 2020-2026

Data provided by Accord Fintech

Made with ❤️ in India.

HomeScreens
Login